Skip to content

The safety and efficacy of Fibrin sealant Thai Red Cross Society compared with commercially Fibrin sealant in pterygium volunteer

Phase II/III open-label randomized-controlled trial to evaluate the safety and efficacy of Fibrin sealant Thai Red Cross Society compared with commercially available fibrin sealant (TISSEEL) in pterygium volunteer

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240723010
Enrollment
44
Registered
2024-07-23
Start date
2024-10-09
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pterygium patients in the Ophthalmology clinic of King Chulalongkorn Memorial Hospital Pterygium, Fibrin Sealant, conjunctival autograft surgery

Interventions

IP name : Fibrin sealant TRCS Drug substance : 1. Sealer protein solution: Human fibrinogen 60 mg/ML 2. Thrombin solution: Human thrombin 500 IU/ML Pharmaceutical form : Solution Appearance: Colo
Experimental Drug,Active Comparator Drug

Sponsors

Health Systems Research Institute (HSRI)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Primary pterygium grade T1 or T2 with indication for surgical excision Classification of Pterygium Morphology: Grade T1 = Atrophic pterygium, episcleral vessels unobscured Grade T2 = Intermediate pterygium, episcleral vessels partially obscured Grade T3 = Fleshy pterygium, episcleral vessels totally obscured 2. Voluntary informed consent obtained from the patient who is available to come on follow-up visits as indicated in protocol

Exclusion criteria

Exclusion criteria: 1. Currently on topical medication except artificial tears or lubricant gel 2. Diagnosed with ocular surface disease except pterygium, meibomian gland dysfunction, and dry eyes 3. Contraindicated for pterygium surgery with conjunctival autograft such as glaucoma or pseudopterygium 4. Previous conjunctival surgery such as previous pterygium surgery, strabismus surgery or conjunctival mass excision 5. Indicated to combine pterygium surgery with other procedure such as cataract surgery 6. Indicated to combine pterygium surgery with mitomycin-C 7. Pregnancy 8. Preexisting positive serologic test (HBsAg, anti-HCV, anti-HIV or anti-TP)

Design outcomes

Primary

MeasureTime frame
graft attachment at 1week post-pterygium excision Rate of graft attachment

Secondary

MeasureTime frame
Surgical-related complications including: graft loss, infection (keratitis/conjunctivitis/scleritis), excessive ocular surface inflammation, recurrent pterygium within postoperative 3 months Slit lamp photography,Operative time and intraoperative graft attachment time after pterygium excision time count,Pain at surgical area Day 1 post operation numerical pain score ,Surgeon rated satisfaction at the end of the operation Surgeon rated satisfaction score,Satisfaction by assessor Month 1 post operation Satisfaction score by assessor via photo

Countries

Thailand

Contacts

Public ContactAsst. Prof. Vilavun Puangsricharern

Faculty of Medicine, Chulalongkorn University

vilavan@hotmail.com0830122999

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026